Loading...

Global Blood Therapeutics

DB:G5B
Snowflake Description

Flawless balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
G5B
DB
$3B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Global Blood Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. The last earnings update was 49 days ago. More info.


Add to Portfolio Compare Print
  • Global Blood Therapeutics has significant price volatility in the past 3 months.
G5B Share Price and Events
7 Day Returns
-0.6%
DB:G5B
0.3%
DE Biotechs
2.3%
DE Market
1 Year Returns
37.8%
DB:G5B
-7.9%
DE Biotechs
-7.2%
DE Market
G5B Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Global Blood Therapeutics (G5B) -0.6% 10.1% 24.7% 37.8% 178.9% -
DE Biotechs 0.3% 3.1% -6.5% -7.9% 43.5% 7.6%
DE Market 2.3% 3.1% 8.8% -7.2% 9.3% 12.3%
1 Year Return vs Industry and Market
  • G5B outperformed the Biotechs industry which returned -7.9% over the past year.
  • G5B outperformed the Market in Germany which returned -7.2% over the past year.
Price Volatility
G5B
Industry
5yr Volatility vs Market
Related Companies

G5B Value

 Is Global Blood Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Global Blood Therapeutics to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Global Blood Therapeutics.

DB:G5B Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 13 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:G5B
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.46
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.456 (1 + (1- 21%) (0%))
1.306
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.31
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.306 * 5.96%)
8.01%

Discounted Cash Flow Calculation for DB:G5B using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Global Blood Therapeutics is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:G5B DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8.01%)
2019 -219.79 Analyst x3 -203.49
2020 -238.90 Analyst x3 -204.79
2021 72.52 Analyst x1 57.56
2022 521.23 Analyst x1 382.99
2023 1,178.65 Analyst x1 801.84
2024 1,394.95 Est @ 18.35% 878.61
2025 1,575.09 Est @ 12.91% 918.52
2026 1,718.55 Est @ 9.11% 927.86
2027 1,829.30 Est @ 6.44% 914.42
2028 1,913.07 Est @ 4.58% 885.38
Present value of next 10 years cash flows $5,358.91
DB:G5B DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $1,913.07 × (1 + 0.23%) ÷ (8.01% – 0.23%)
$24,642.53
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $24,642.53 ÷ (1 + 8.01%)10
$11,404.77
DB:G5B Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $5,358.91 + $11,404.77
$16,763.68
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $16,763.68 / 56.32
$297.64
DB:G5B Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:G5B represents 0.8991x of NasdaqGS:GBT
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.8991x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 297.64 x 0.8991
€267.61
Value per share (EUR) From above. €267.61
Current discount Discount to share price of €50.88
= -1 x (€50.88 - €267.61) / €267.61
81%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Global Blood Therapeutics is available for.
Intrinsic value
>50%
Share price is €50.88 vs Future cash flow value of €267.61
Current Discount Checks
For Global Blood Therapeutics to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Global Blood Therapeutics's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Global Blood Therapeutics's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Global Blood Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Global Blood Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:G5B PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-3.41
NasdaqGS:GBT Share Price ** NasdaqGS (2019-04-17) in USD $56.59
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 23.37x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.43x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Global Blood Therapeutics.

DB:G5B PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:GBT Share Price ÷ EPS (both in USD)

= 56.59 ÷ -3.41

-16.62x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Global Blood Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Global Blood Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Global Blood Therapeutics's expected growth come at a high price?
Raw Data
DB:G5B PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -16.62x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 13 Analysts
58%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.31x
Germany Market PEG Ratio Median Figure of 272 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Global Blood Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Global Blood Therapeutics's assets?
Raw Data
DB:G5B PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $10.29
NasdaqGS:GBT Share Price * NasdaqGS (2019-04-17) in USD $56.59
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.89x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.87x
DB:G5B PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:GBT Share Price ÷ Book Value per Share (both in USD)

= 56.59 ÷ 10.29

5.5x

* Primary Listing of Global Blood Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Global Blood Therapeutics is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Global Blood Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Global Blood Therapeutics has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

G5B Future Performance

 How is Global Blood Therapeutics expected to perform in the next 1 to 3 years based on estimates from 13 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
58%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Global Blood Therapeutics expected to grow at an attractive rate?
  • Global Blood Therapeutics's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Global Blood Therapeutics's earnings growth is expected to exceed the Germany market average.
  • Unable to compare Global Blood Therapeutics's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:G5B Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:G5B Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 13 Analysts 58%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.6%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:G5B Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 13 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:G5B Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 1,122 1,318 554 7
2022-12-31 600 580 269 8
2021-12-31 311 57 23 11
2020-12-31 74 -172 -190 13
2019-12-31 0 -199 -220 13
DB:G5B Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 -135 -174
2018-09-30 -127 -166
2018-06-30 -122 -152
2018-03-31 -107 -135
2017-12-31 -93 -117
2017-09-30 -88 -103
2017-06-30 -81 -95
2017-03-31 -76 -89
2016-12-31 -68 -82
2016-09-30 -57 -71
2016-06-30 -47 -65
2016-03-31 -39 -58

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Global Blood Therapeutics's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if Global Blood Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:G5B Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 13 Analyst Estimates (S&P Global) See Below

All data from Global Blood Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:G5B Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 8.66 17.57 4.37 6.00
2022-12-31 3.95 7.59 1.61 6.00
2021-12-31 0.27 1.30 -0.83 7.00
2020-12-31 -3.02 -0.83 -4.42 10.00
2019-12-31 -3.91 -2.92 -4.55 12.00
DB:G5B Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -3.41
2018-09-30 -3.40
2018-06-30 -3.25
2018-03-31 -3.04
2017-12-31 -2.76
2017-09-30 -2.54
2017-06-30 -2.46
2017-03-31 -2.50
2016-12-31 -2.48
2016-09-30 -2.25
2016-06-30 -2.45
2016-03-31 -2.98

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Global Blood Therapeutics is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Global Blood Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Global Blood Therapeutics has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

G5B Past Performance

  How has Global Blood Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Global Blood Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Global Blood Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Global Blood Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Global Blood Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Global Blood Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Global Blood Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:G5B Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -174.19 51.44 131.31
2018-09-30 -166.24 48.34 124.24
2018-06-30 -151.73 42.51 113.76
2018-03-31 -135.25 37.75 100.47
2017-12-31 -117.02 31.44 87.81
2017-09-30 -102.98 26.97 76.32
2017-06-30 -95.41 23.67 71.58
2017-03-31 -89.20 22.20 66.43
2016-12-31 -82.47 20.36 61.26
2016-09-30 -70.85 19.51 51.76
2016-06-30 -65.41 16.15 48.75
2016-03-31 -58.48 12.99 42.70
2015-12-31 -50.54 9.74 36.66
2015-09-30 -41.17 6.79 29.32
2015-06-30 -31.61 5.25 21.28
2015-03-31 -26.73 4.55 18.52
2014-12-31 -23.77 4.19 16.32
2013-12-31 -19.85 2.81 12.86

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Global Blood Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Global Blood Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Global Blood Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Global Blood Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Global Blood Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

G5B Health

 How is Global Blood Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Global Blood Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Global Blood Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Global Blood Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Global Blood Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Global Blood Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Global Blood Therapeutics Company Filings, last reported 3 months ago.

DB:G5B Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 572.80 0.00 477.53
2018-09-30 472.20 0.00 383.23
2018-06-30 506.55 0.00 462.48
2018-03-31 537.76 0.00 543.59
2017-12-31 318.80 0.00 314.83
2017-09-30 258.27 0.00 219.36
2017-06-30 281.71 0.00 229.82
2017-03-31 302.49 0.00 244.32
2016-12-31 186.31 0.00 147.27
2016-09-30 210.10 0.00 217.84
2016-06-30 222.41 0.00 231.91
2016-03-31 126.12 0.00 133.98
2015-12-31 140.80 0.00 148.50
2015-09-30 154.82 0.00 158.50
2015-06-30 37.88 0.00 40.58
2015-03-31 45.75 0.00 45.80
2014-12-31 52.84 0.00 52.07
2013-12-31 2.25 0.00 3.28
  • Global Blood Therapeutics has no debt.
  • Global Blood Therapeutics has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Global Blood Therapeutics has sufficient cash runway for more than 3 years based on current free cash flow.
  • Global Blood Therapeutics has sufficient cash runway for 2.5 years if free cash flow continues to grow at historical rates of 42.7% each year.
X
Financial health checks
We assess Global Blood Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Global Blood Therapeutics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

G5B Dividends

 What is Global Blood Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Global Blood Therapeutics dividends. Estimated to be 0% next year.
If you bought €2,000 of Global Blood Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Global Blood Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Global Blood Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:G5B Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 13 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 325 Stocks 3.1%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:G5B Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Global Blood Therapeutics has not reported any payouts.
  • Unable to verify if Global Blood Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Global Blood Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Global Blood Therapeutics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Global Blood Therapeutics's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Global Blood Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Global Blood Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Global Blood Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

G5B Management

 What is the CEO of Global Blood Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Ted Love
COMPENSATION $8,018,998
AGE 59
TENURE AS CEO 4.8 years
CEO Bio

Dr. Ted W. Love, M.D. has been the Chief Executive Officer and President of Global Blood Therapeutics, Inc. since June 2014. Dr. Love serves as a Senior Medical Advisor of Ivivi Health Sciences, LLC. He served as a Consultant of Onyx Pharmaceuticals, Inc. from August 1, 2012 to December 31, 2012. He served as an Executive Vice President of Onyx Pharmaceuticals, Inc. from February 1, 2010 to August 1, 2012 and served as its Head of Research and Development from February 1, 2010 to January 2011 and Head of Research & Development and Technical Operations from January 2011 to August 1, 2012. He served as the President of Nuvelo Inc., from January 2001 to 2009 and its Chief Executive Officer from March 2001 to 2009. He served as the Chief Operating Officer of Nuvelo Inc., from January 2001 to March 2001. Before joining Nuvelo in 2001, he served as a Senior Vice President of Development at Theravance Inc. (formerly known as Advanced Medicine Inc.) from February 1998 to January 2001. Dr. Love spent six years at Genentech Inc. in a number of senior management positions in Medical Affairs and Product Development. Dr. Love served as a Research Physician and Vice President of Product Development and Regulatory Affairs at Genentech from 1992 to 1998, he oversaw all drugs in development including Herceptin (R), Rituxan(R) and TNKase(TM). He served as the Chairman of KaloBios Pharmaceuticals, Inc. since May 1, 2014 until May 2015. He served as the Chairman at Nuvelo Inc., from September 2005 to 2009. He serves as a Director of Oncothyreon and Avillion LLP. He has been an Independent Director at Amicus Therapeutics, Inc. since June 13, 2012. He served as an Independent Director of Cascadian Therapeutics, Inc. since September 06, 2013 to until March 9, 2018. He serves as a Director of California Life Sciences Association (formerly California Healthcare Institute). Dr. Love has been a Director at Global Blood Therapeutics, Inc. since September 2013. He serves as a Trustee on the board of managers of Haverford College. Dr. Love served as a Director of KaloBios Pharmaceuticals, Inc. since March 2009 until November 19, 2015 and its Lead Independent Director since May 2015 until November 19, 2015. He served as a Director of Santarus Inc. from March 18, 2005 to January 2, 2014. He served as Director of Stanford Health Care (formerly Stanford Hospital & Clinics). Dr. Love served as a Director of Affymax, Inc. from June 2006 to June 4, 2013. He served as a Director of Mast Therapeutics, Inc. from September 7, 2012 to August 6, 2013. He served as a Director of Bio-Rad Laboratories, Inc., from 2010 to April 23, 2013. He served as a Director of Anesiva, Inc. since November 23, 2009; ARCA biopharma, Inc. from February 2001 to March 22, 2011; Nuvelo Inc. from February 2001 to 2009; Predix Pharmaceuticals Holdings, Inc. since September 2003 and Predix Pharmaceuticals, Inc. Dr. Love served as the Chairman of Genentech's Product Development Committee. He also served as a member of the Independent California Oversight Committee (ICOC) for Stem Cell Research. He completed his Residency and Fellowship training in Internal Medicine and Cardiology at Massachusetts General Hospital and Harvard Medical School. Following residency training, he joined the faculty of Massachusetts General in the department of cardiology. Dr. Love holds a B.A. in Molecular Biology from Haverford College at Massachusetts General Hospital and an M.D. from Yale Medical School.

CEO Compensation
  • Ted's compensation has increased whilst company is loss making.
  • Ted's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Global Blood Therapeutics management team in years:

4.8
Average Tenure
56
Average Age
  • The tenure for the Global Blood Therapeutics management team is about average.
Management Team

Ted Love

TITLE
President
COMPENSATION
$8M
AGE
59
TENURE
4.8 yrs

Charles Homcy

TITLE
Founder
COMPENSATION
$298K
AGE
70
TENURE
8.3 yrs

Jeff Farrow

TITLE
Chief Financial Officer
COMPENSATION
$2M
AGE
56
TENURE
3 yrs

Peter Radovich

TITLE
Senior Vice President of Operations
COMPENSATION
$1M
AGE
40
TENURE
2.6 yrs

Hing Sham

TITLE
Senior Vice President of Research
COMPENSATION
$1M
AGE
66
TENURE
4.8 yrs

Jung Choi

TITLE
Chief Business & Strategy Officer
COMPENSATION
$2M
AGE
48
TENURE
4 yrs

David Phillips

TITLE
Founder & Advisor
TENURE
8.3 yrs

Matthew Jacobson

TITLE
Founder & Advisor
TENURE
8.3 yrs

Andrej Sali

TITLE
Founder & Advisor
TENURE
8.3 yrs

Lesley Calhoun

TITLE
Senior VP of Finance & Chief Accounting Officer
AGE
52
TENURE
2.6 yrs
Board of Directors Tenure

Average tenure and age of the Global Blood Therapeutics board of directors in years:

3.6
Average Tenure
62.5
Average Age
  • The tenure for the Global Blood Therapeutics board of directors is about average.
Board of Directors

Charles Homcy

TITLE
Founder
COMPENSATION
$298K
AGE
70
TENURE
8.2 yrs

Willie Brown

TITLE
Director
COMPENSATION
$301K
AGE
84
TENURE
4.3 yrs

Ted Love

TITLE
President
COMPENSATION
$8M
AGE
59
TENURE
5.6 yrs

Mark Perry

TITLE
Lead Independent Director
COMPENSATION
$310K
AGE
62

Scott Morrison

TITLE
Director
COMPENSATION
$308K
AGE
60
TENURE
3.3 yrs

Deval Patrick

TITLE
Director
COMPENSATION
$316K
AGE
61
TENURE
4 yrs

Philip Pizzo

TITLE
Director
COMPENSATION
$302K
AGE
73
TENURE
3.6 yrs

Glenn Pierce

TITLE
Director
COMPENSATION
$303K
AGE
62
TENURE
3.2 yrs

Wendy Yarno

TITLE
Director
COMPENSATION
$716K
AGE
63
TENURE
1.3 yrs

Graham Svoronos

TITLE
Director
AGE
65
TENURE
0.3 yrs
Who owns this company?
Recent Insider Trading
  • Global Blood Therapeutics insiders have only sold shares in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
14. Feb 19 Sell Lesley Calhoun Individual 12. Feb 19 12. Feb 19 -354 €44.59 €-15,783
14. Feb 19 Sell Lesley Calhoun Individual 01. Aug 18 01. Aug 18 -258 €37.30 €-9,623
14. Feb 19 Sell Lesley Calhoun Individual 15. Mar 18 03. Jul 18 -697 €46.90 €-31,120
21. Aug 18 Sell Lesley Calhoun Individual 16. Aug 18 17. Aug 18 -504 €43.78 €-21,861
X
Management checks
We assess Global Blood Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Global Blood Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

G5B News

Simply Wall St News

G5B Company Info

Description

Global Blood Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD. It is also evaluating the safety and pharmacokinetics of single and multiple doses of voxelotor in a Phase IIa clinical trial of adolescent and pediatric patients with SCD. Global Blood Therapeutics, Inc. was founded in 2011 and is headquartered in South San Francisco, California.

Details
Name: Global Blood Therapeutics, Inc.
G5B
Exchange: DB
Founded: 2011
$2,820,420,995
56,322,257
Website: http://www.gbt.com
Address: Global Blood Therapeutics, Inc.
171 Oyster Point Boulevard,
Suite 300,
South San Francisco,
California, 94080,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS GBT Common Stock Nasdaq Global Select US USD 12. Aug 2015
DB G5B Common Stock Deutsche Boerse AG DE EUR 12. Aug 2015
LSE 0IVZ Common Stock London Stock Exchange GB USD 12. Aug 2015
Number of employees
Current staff
Staff numbers
171
Global Blood Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/17 23:32
End of day share price update: 2019/04/17 00:00
Last estimates confirmation: 2019/04/12
Last earnings filing: 2019/02/27
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.